Tag Archives: Market Access

Bringing New Rx Drugs to Market in 2014

by Tom Norton I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide […]
Posted in Biotech, Corporate Responsibility, Emerging Markets, Europe, FDA, Global, Guest Blog, Market Access, pricing, Strategy | Also tagged , , , , , | 3 Comments

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, IP, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , | Leave a comment

Three Capabilities You Must Build Today to
Ensure Market Access Tomorrow

By Howard Deutsch, Associate Principal, ZS Associates (Sponsored Content) Oncology-market access doesn’t “just happen” anymore. As competition in the U.S. health-care market only continues to intensify, oncology-drug companies will need a good corporate strategy to ensure physician uptake and payer coverage of therapies. Having strong clinical data isn’t enough, especially as stakeholders grow ever more […]
Posted in Strategy | Also tagged , | Leave a comment

The First Day of Obamacare: Is US Pharma Ready?

by Tom Norton For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare — and enjoy the prospect of prescription drug insurance, effective January 1st, 2014. I have spent the last week surveying many […]
Posted in Guest Blog, healthcare, Legal, Market Access, pricing, R&D, Regulatory, Sales, Strategy | Also tagged , , , , , , , | 1 Comment

Market Access is Dead: Patient Access is the New Prescription for Healthcare Marketing

by John Glasspool Paradigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. Initially a topic for pharmaceutical companies concerned about volume, it now affects all aspects of healthcare. We believe […]
Posted in Global, Market Access, Strategy | Also tagged , , , , , , , , | 5 Comments
  • Categories

  • Meta